Lorecivivint, page-18

Mangoman are you aware if they have done any scoping studies like us in regards to the potential cost of their treatment?

If their product does work, is DMOAD, and gains FDA approval I could see them having an advantage of a single injection as opposed to having to go back to your Dr 2 x week (potentially 1 x a week) for 5/6 weeks like with our drug. If this gets up I could see Drs prescribing this as a first line to iPPS due to the convenience factor, and likely at a much cheaper cost than iPPS.

Of course those in pain would be willing to go back to the Dr as many times as needed to get a superior drug but if they do get FDA approval they would have serious first mover advantage on us. They will have the marketing networks and patient world of mouth in full force years ahead of us and once it is being prescribed by Doctors it, Paradigm would have trouble convincing Doctors why they should potentially be dosing their patient with another drug at a much greater expense and inconvenience to the patient when there is one which has shown to have decent results.

Cheers